US2018208668A1PendingUtilityA1

OPTIMIZED Fc VARIANTS

Assignee: XENCOR INCPriority: May 2, 2003Filed: Dec 12, 2017Published: Jul 26, 2018
Est. expiryMay 2, 2023(expired)· nominal 20-yr term from priority
A61P 43/00A61K 2039/505C07K 16/2887C07K 2317/64C07K 2317/40C07K 16/2896C07K 16/2893C07K 2317/734C07K 2317/72C07K 2317/94C07K 16/00C07K 2317/52C07K 16/30C07K 2317/77C07K 2317/41C07K 2317/34C07K 2317/732C07K 2317/71C07K 16/2863C07K 2317/31C07K 16/32C07K 16/18C07K 2317/24C07K 2317/92C07K 2317/56
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . A protein comprising an Fc variant of parent Fc polypeptide, said Fc variant comprising an amino acid substitution in the Fc region selected from 267D and 267E, and wherein numbering is according to the EU index. 
     
     
         3 . A protein comprising an Fc variant of a human IgG1 Fc polypeptide, said Fc variant comprising an amino acid substitution in the Fc region selected from P228E, P228G, P228K and P228Y, wherein numbering is according to the EU index.

Join the waitlist — get patent alerts

Track US2018208668A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.